Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2− Metastatic Breast Cancer

被引：0
|
作者：
Anand A. Dalal
Patrick Gagnon-Sanschagrin
Rebecca Burne
Annie Guérin
Geneviève Gauthier
Tania Small
Polly Niravath
机构：
[1] Novartis Pharmaceuticals Corporation,
[2] Analysis Group,undefined
[3] Inc.,undefined
[4] Houston Methodist Hospital,undefined
来源：
Advances in Therapy | 2018年 / 35卷
关键词：
Dose modification; Drug wastage; Economic burden; HR+/HER2− metastatic breast cancer; Oncology; Palbociclib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：768 / 778
页数：10
相关论文
共 50 条
  • [1] Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2-Metastatic Breast Cancer
    Dalal, Anand A.
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Gauthier, Genevieve
    Small, Tania
    Niravath, Polly
    ADVANCES IN THERAPY, 2018, 35 (06) : 768 - 778
  • [2] Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2-metastatic breast cancer
    Li, Nanxin
    Du, Ella X.
    Chu, Lihao
    Peeples, Miranda
    Xie, Jipan
    Barghout, Victoria
    Tang, Derek H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (12) : 1167 - 1178
  • [3] Patterns and outcomes in HR+/HER2-advanced/metastatic breast cancer patients in Brazil receiving palbociclib
    Simon, Patricia
    Jain, Ankita
    Guarin, Alexandra
    Piton, Luciana
    Carvalho, Carla Fabrine
    Lima, Julia
    Nazareth, Felipe
    FUTURE ONCOLOGY, 2024, : 2647 - 2659
  • [4] Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women
    Geneviève Gauthier
    Patrick Gagnon-Sanschagrin
    Annie Guérin
    Rebecca Burne
    Tania Small
    Polly Niravath
    Anand A. Dalal
    Advances in Therapy, 2018, 35 : 503 - 514
  • [5] Economic Burden of HR+/HER2-Metastatic Breast Cancer Among Adult Premenopausal Women
    Gauthier, Genevieve
    Gagnon-Sanschagrin, Patrick
    Guerin, Annie
    Burne, Rebecca
    Small, Tania
    Niravath, Polly
    Dalal, Anand A.
    ADVANCES IN THERAPY, 2018, 35 (04) : 503 - 514
  • [6] Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer
    Ban, Marija
    Mise, Branka Petric
    Majic, Ana
    Drazic, Ivanka
    Vrdoljak, Eduard
    FUTURE ONCOLOGY, 2018, 14 (06) : 537 - 544
  • [7] Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
    Christiansen, Emilie Adrian
    Kuemler, Iben
    FUTURE SCIENCE OA, 2024, 10 (01):
  • [8] Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2− Advanced Breast Cancer
    Anand A. Dalal
    Geneviève Gauthier
    Patrick Gagnon-Sanschagrin
    Rebecca Burne
    Annie Guérin
    Polly Niravath
    Tania Small
    Advances in Therapy, 2018, 35 : 1356 - 1367
  • [9] A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2-metastatic breast cancer
    Li, Yi
    Li, Wei
    Gong, Chengcheng
    Zheng, Yabin
    Ouyang, Quchang
    Xie, Ning
    Qu, Qing
    Ge, Rui
    Wang, Biyun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [10] Real-world study of patients with HR+/ HER2-metastatic breast cancer treated with palbociclib and fulvestrant
    Robert, Nicholas
    Chen, Connie
    Doan, Justin
    Venkatasetty, Divea
    Espirito, Janet L.
    Aguilar, Kathleen M.
    FUTURE ONCOLOGY, 2025, 21 (01) : 83 - 94
12345